Costs of medications used to treat inflammatory bowel disease

References

• Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380(9853):1590–1605. doi: 10.1016/S0140-6736(12)60026-9.
   PubMed Web of Science ®Google Scholar
• Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380(9853):1606–1619. doi: 10.1016/S0140-6736(12)60150-0.
   PubMed Web of Science ®Google Scholar
• Zhao M, Gönczi L, Lakatos PL, et al. The burden of inflammatory bowel disease in Europe in 2020. J Crohns Colitis. 2021;15(9):1573–1587. doi: 10.1093/ecco-jcc/jjab029.
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778. doi: 10.1016/S0140-6736(17)32448-0.
   PubMed Web of Science ®Google Scholar
• Côté-Daigneault J, Bouin M, Lahaie R, et al. Biologics in inflammatory bowel disease: what are the data? United European Gastroenterol J. 2015;3(5):419–428. doi: 10.1177/2050640615590302.
   PubMed Web of Science ®Google Scholar
• Saro C, da la Coba C, Casado MA, et al. Resource use in patients with Crohn’s disease treated with infliximab. Aliment Pharmacol Ther. 2007;26(10):1313–1323. doi: 10.1111/j.1365-2036.2007.03507.x.
   PubMed Web of Science ®Google Scholar
• Targownik LE, Benchimol EI, Witt J, et al. The effect of initiation of anti-TNF therapy on the subsequent direct health care costs of inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(10):1718–1728. doi: 10.1093/ibd/izz063.
   PubMed Web of Science ®Google Scholar
• Lindsay JO, Chipperfield R, Giles A, et al. A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn’s disease. Aliment Pharmacol Ther. 2013;38(1):52–61. doi: 10.1111/apt.12339.
   PubMed Web of Science ®Google Scholar
• Kawalec P, Mikrut A, Łopuch S. Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis. J Gastroenterol Hepatol. 2014;29(6):1159–1170. doi: 10.1111/jgh.12563.
   PubMed Web of Science ®Google Scholar
• Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25. doi: 10.1093/ecco-jcc/jjw168.
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ. Thiopurines and methotrexate use in IBD patients in a biologic era. Curr Treat Options Gastroenterol. 2017;15(1):84–104. doi: 10.1007/s11938-017-0128-0.
   PubMedGoogle Scholar
• Ford AC, Moayyedi P, Hanauer SB, et al. Ulcerative colitis. BMJ. 2013;346(7894):f432. doi: 10.1136/bmj.f432.
   PubMedGoogle Scholar
• Axelrad JE, Roy A, Lawlor G, et al. Thiopurines and inflammatory bowel disease: current evidence and a historical perspective. World J Gastroenterol. 2016;22(46):10103–10117. doi: 10.3748/wjg.v22.i46.10103.
   PubMed Web of Science ®Google Scholar
• Van Der Valk ME, Mangen MJJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2014;63(1):72–79. doi: 10.1136/gutjnl-2012-303376.
   PubMed Web of Science ®Google Scholar
• Lo B, Vind I, Vester-Andersen MK, et al. Direct and indirect costs of inflammatory bowel disease: ten years of follow-up in a Danish population-based inception cohort. J Crohns Colitis. 2020;14(1):53–63. doi: 10.1093/ecco-jcc/jjz096.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Longobardi T, Finlayson G, et al. Direct medical cost of managing IBD patients: a Canadian population-based study. Inflamm Bowel Dis. 2012;18(8):1498–1508. doi: 10.1002/ibd.21878.
   PubMed Web of Science ®Google Scholar
• Niewiadomski O, Studd C, Hair C, et al. Health care cost analysis in a population-based inception cohort of inflammatory bowel disease patients in the first year of diagnosis. J Crohns Colitis. 2015;9(11):988–996. doi: 10.1093/ecco-jcc/jjv117.
   PubMed Web of Science ®Google Scholar
• Rankala R, Kosonen J, Mattila K, et al. Direct costs of inflammatory bowel diseases in a Finnish tertiary-level clinic. Frontline Gastroenterol. 2021;12(5):385–389. doi: 10.1136/flgastro-2020-101466.
   PubMed Web of Science ®Google Scholar
• Irvine E, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology. 1994;106(2):287–296. doi: 10.1016/0016-5085(94)90585-1.
   PubMed Web of Science ®Google Scholar
• Han S-W, McColl E, Steen N, et al. The inflammatory bowel disease questionnaire: a valid and reliable measure in ulcerative colitis patients in the North East of England. Scand J Gastroenterol. 1998;33(9):961–966. doi: 10.1080/003655298750026994.
   PubMed Web of Science ®Google Scholar
• Burisch J, Vardi H, Pedersen N, et al. Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom study. Inflamm Bowel Dis. 2015;21(1):121–131. doi: 10.1097/MIB.0000000000000250.
   PubMed Web of Science ®Google Scholar
• Lawton J, Achit H, Pouillon L, et al. Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: a French large single-centre experience. United Eur Gastroenterol J. 2019;7(7):908–913. doi: 10.1177/2050640619853448.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Panés J, Sandborn WJ, et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol. 2016;14(3):348–354.e17. doi: 10.1016/j.cgh.2015.06.001.
   PubMed Web of Science ®Google Scholar
• Larsen BA. Prescription drugs that are not dispensed. Tidsskr nor Laegeforen. 2020;140(13):1–5. doi: 10.4045/tidsskr.19.0577.
   Web of Science ®Google Scholar
• Shin J, McCombs JS, Sanchez RJ, et al. Primary nonadherence to medications in an integrated healthcare setting. Am J Manag Care. 2012;18(8):426–434. PMID: 22928758.
   PubMed Web of Science ®Google Scholar
• Pottegård A, Christensen RD, Houji A, et al. Primary non-adherence in general practice: a danish register study. Eur J Clin Pharmacol. 2014;70(6):757–763. doi: 10.1007/s00228-014-1677-y.
   PubMed Web of Science ®Google Scholar